2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique

Breast Cancer Research and Treatment

Volumn 111, Issue 2, 2008, Pages 251-260

  Foster, Paul A ^a   Ho, Yaik T ^a   Newman, Simon P ^a   Kasprzyk, Philip G ^b   Leese, Mathew P ^c   Potter, Barry V L ^c   Reed, Michael J ^a   Purohit, Atul ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Biomeasure Inc   (United States)

^c UNIVERSITY OF BATH   (United Kingdom)

Author keywords

2 Methoxyestradiol; Apoptosis; Breast cancer; Estrogen; Sulfamate

Indexed keywords

2 ETHYLESTRADIOL 3,17 O,O BISSULFAMATE; 2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL 3,17 O,O BISSULFAMATE; BEVACIZUMAB; COLCHICINE; CYTOCHROME C; ESTROGEN; NAVELBINE; PACLITAXEL; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOXICITY; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL ENERGY TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENERGY METABOLISM; ESTRADIOL; FEMALE; HUMANS; MICE; NEOPLASM TRANSPLANTATION; SULFONIC ACIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 48149110838     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9791-5     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics. CA Cancer J Clin 55:77-108
2. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 48:2431-2442
3. Stanway SJ, Purohit A, Woo LWL et al (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 12:1585-1592
4. Nabholtz JM, Gligorov J (2005) The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 6:1073-1094
5. Shak S (1999) Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 26:71-77
6. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
7. Vacca A, Iurlaro M, Ribatti D et al (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143-4155
8. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24
9. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 5:1045-1047
10. Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346
11. Zhu BT, Conney AH (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58:2269-2277
12. Pribluda VS, Gubish ER Jr, Lavallee TM et al (2000) 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19:173-179
13. Shang W, Konidari I, Schomberg DW (2001) 2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod 65:622-627
14. Dingli D, Timm M, Russell SJ et al (2002) Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 8:3948-3954
15. Lakhani NJ, Sarkar MA, Venitz J et al (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165-172
16. Mooberry SL (2003) New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15:425-430
17. Dahut WL, Lakhani NJ, Gulley JL et al (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5:22-27
18. Newman SP, Ireson CR, Tutill HJ et al (2006) The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 66:324-330
19. Purohit A, Hejaz HA, Walden L et al (2000) The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 85:584-589
20. MacCarthy-Morrogh L, Townsend PA, Purohit A et al (2000) Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 60:5441-5450
21. Raobaikady B, Reed MJ, Leese MP et al (2005) Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates. Int J Cancer 117:150-159
22. Newman SP, Leese MP, Purohit A et al (2004) Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109:533-540
23. Chander SK, Foster PA, Leese MP et al (2007) In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 96:1368-1376
24. Ireson CR, Chander SK, Purohit A et al (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90:932-937
25. Leese MP, Leblond B, Smith A et al (2006) 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 28:7683-7696
26. Reers M, Smith TW, Chen LB (1991) J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30:4480-4486
27. Reers M, Smiley ST, Mottola-Hartshorn C et al (1995) Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol 260:406-417
28. Di Lisa F, Blank PS, Colonna R et al (1995) Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J Physiol (Lond) 486:1-13
29. Ellison G, Klinowska T, Westwood RFR et al (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294-299
30. Sellappan S, Grijalva R, Zhou X et al (2004) Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64:3469-3485
31. Rae JM, Creighton CJ, Meck JM et al (2007) MDA-MB-435 cells are derived from M14 Melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-19
32. Day JM, Newman SP, Comninos A et al (2003) The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 84:317-325
33. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 30:626-629